5/20/2025- Dr. Kelly Gwathmey interviews Dr. Corey Bacher from the University of Toronto, Dr. Charles Kassardjian from the University of Toronto, both in Toronto, Ontario, Canada. We also have Dr. Ruple Laughlin from the Mayo Clinic in Rochester, Minnesota, and Dr. Puspha Narayanswami from Beth Israel Deaconess Medical Center in Boston, Massachusetts. They will all be discussing recommendations for monitoring and managing glucocorticoid related systemic complications from the recently published: “International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease." 25 min
1/30/2025-In this AANEM podcast, Dr. Stino interviews Dr. Allen on the groundbreaking ADHERE study, published in Lancet Neurology in 2024, which investigated efgartigimod for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). As the largest CIDP trial to date with 322 patients across 146 sites, it marked the first major study of a targeted biologic therapy in CIDP. The trial featured a unique two-stage design: an open-label response phase followed by a randomized controlled phase for responders. Dr. Allen explains the rationale behind targeting IgG in CIDP, despite its less clear antibody-mediated mechanism compared to myasthenia gravis. The study demonstrated a 66-70% response rate in the open-label phase, with significantly lower relapse rates compared to placebo in the randomized phase. This research represents a significant advancement in CIDP treatment options, offering a weekly subcutaneous administration that could reduce treatment burden compared to traditional therapies. 31 min.
9/30/2024- Despite its recognition for nearly 40 years, anti-MAG neuropathy continues to have limited therapeutic options. The emergence of bruton tyrosine kinase inhibition as a new therapeutic pathway appears promising. In this interview, Dr. Amro Stino interviews Dr. Chiara Briani on her 2023 paper exploring the prevalence of the MYD 88 mutation among patients with anti-MAG neuropathy. This is discussed within the broader context of disease presentation, current treatment landscape, and future drug development. - 29 minutes
4/15/2024 -Drs. Mohamed Taha and John Morren speak with Andy Galbreath about their recent Muscle & Nerve paper on Artificial Intelligence in NM and EDX Medicine. The authors discuss concepts of machine learning, deep learning, and artificial neural networks as they relate to NM and EDX medicine. Limitations and regulatory challenges are also discussed. Muscle & Nerve. 2024;69:260-272. 35 min.